OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

OXFORD BIOMEDICA LS-,50/  GB00BDFBVT43  /

München
2024-11-13  8:15:06 AM Chg. 0.000 Volume Bid9:57:46 PM Ask9:57:46 PM Market Capitalization Dividend Y. P/E Ratio
4.980EUR 0.00% 0
Turnover: 0.000		 -Bid Size: - -Ask Size: - 399.03 mill.EUR - -
GlobeNewswire 09-02 Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
GlobeNewswire 08-27 Oxford Biomedica to host a free webinar showcasing its AAV expertise
GlobeNewswire 08-08 Aligos Therapeutics Strengthens Board with Two New Independent Directors
GlobeNewswire 08-08 Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
GlobeNewswire 08-06 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 07-25 Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
GlobeNewswire 07-17 Oxford Biomedica announces CFO transition
GlobeNewswire 04-01 Autolus Therapeutics Announces Changes to its Board of Directors
GlobeNewswire 03-18 Homology Medicines Declares Distribution to Common Stockholders
GlobeNewswire 03-06 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
GlobeNewswire 03-05 Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
GlobeNewswire 01-29 Oxford Biomedica completes acquisition of ABL Europe
GlobeNewswire 01-23 Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufac...
GlobeNewswire 01-07 Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical ...
GlobeNewswire 01-03 Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire 2023-12-07 Business Update
GlobeNewswire 2023-12-04 Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...
GlobeNewswire 2023-11-16 Q32 Bio and Homology Medicines Announce Merger Agreement
GlobeNewswire 2023-11-14 Homology Medicines Reports Third Quarter 2023 Financial Results
GlobeNewswire 2023-11-09 Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 2023-09-20 Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...
GlobeNewswire 2023-09-20 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
GlobeNewswire 2023-09-07 Oxford Biomedica to host webinar showcasing the TetraVecta™ system
GlobeNewswire 2022-03-23 Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
GlobeNewswire 2022-03-17 Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Upda...